VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Pfizer Inc. vs Sanofi
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Pfizer Inc.
PFE · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Sanofi
SAN · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Sanofi leads (74 / 100 vs 58 / 100 for Pfizer Inc.).
- Segment focus: Pfizer Inc. has 5 segments (47.4% in Primary Care); Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)).
- Moat breadth: Pfizer Inc. has 8 moat types across 3 domains; Sanofi has 5 across 3.
Primary market context
Pfizer Inc.
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Global
Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement
Innovator biopharma (R&D + manufacturing + commercialization)
47.4%
Sanofi
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Global
Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)
Research-based drug developer, manufacturer, and marketer
79.8%
Side-by-side metrics
Moat coverage
Shared moat types
Pfizer Inc. strengths
Sanofi strengths
Segment mix
Pfizer Inc. segments
Full profile >Primary Care
Oligopoly
Specialty Care
Oligopoly
Oncology
Competitive
Pfizer CentreOne
Competitive
Pfizer Ignite
Competitive
Sanofi segments
Full profile >Pharma (Prescription Medicines)
Oligopoly
Vaccines
Oligopoly
Opella (Consumer Healthcare - Sanofi minority stake)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.